Microdosing means injecting the same weekly amount in many small subcutaneous doses instead of one intramuscular shot. The total is unchanged; the peaks are gone. Lower peaks mean less conversion to estrogen, a smaller hematocrit rise, steadier mood, water and libido, and trough values that look like the average. Clinical data on subcutaneous weekly dosing and on frequent dosing support the principle. The cost is more injections and more discipline.
- With a weekly ester injected once a week, serum testosterone swings roughly 2:1 between peak and trough; daily dosing brings the swing to about 1.1:1.
- Aromatisation and erythropoiesis respond to the peak, not the average, so cutting peaks lowers estradiol and hematocrit at the same weekly total.
- Subcutaneous enanthate produced lower hematocrit and estradiol than intramuscular cypionate in a comparison of hypogonadal men; a subcutaneous auto-injector is approved and studied over a year.
- Enanthate and cypionate half-lives of several days make daily or every-other-day dosing practical without accumulation surprises: steady state is reached in four to six weeks.
- Insulin syringes (29–31 gauge) and 0.3–0.5 mL volumes make daily subcutaneous injections painless and quick.
The idea in one graph
One weekly intramuscular injection of enanthate or cypionate: a peak around day one or two at roughly twice the trough, then a slide to the trough by day seven. Daily subcutaneous injections of one seventh of that amount: a nearly flat line at the average. Same total hormone over the week, completely different exposure.
Why the peak matters
Two of the effects you least want scale with the peak, not the average:
- Aromatisation. The enzyme converts a share of available testosterone to estradiol; a high peak floods it, so estrogen spikes on day two and crashes by day seven. That swing is the water retention, mood shift and libido dip many people attribute to “estrogen problems” and then treat with an inhibitor they did not need.
- Erythropoiesis. Red cell production is driven by exposure above the physiological range. Trim the peak and hematocrit rises less at the same weekly total.
Blood pressure, sleep and drive follow the same logic. Flat is quieter.
The evidence
- A weekly subcutaneous enanthate auto-injector is FDA-approved after 26- and 52-week studies with stable trough levels and the expected effects.
- Weekly subcutaneous cypionate kept serum testosterone stable between injections in a published cohort.
- In a comparison of hypogonadal men, subcutaneous enanthate produced lower hematocrit and lower estradiol than intramuscular cypionate.
These studies used weekly subcutaneous dosing. Daily and every-other-day dosing take the same pharmacology further: with a half-life of several days, each small dose stacks on the last and the curve becomes almost a line.
How to set it up
| Item | Practical choice |
|---|---|
| Ester | Enanthate or cypionate |
| Syringe | 1 mL insulin syringe, 29–31 gauge, 0.01 mL graduations |
| Volume per shot | Weekly volume ÷ number of injections; typically 0.1–0.3 mL |
| Sites | Lower abdomen fat, outer thigh; rotate; never the same spot within a week |
| Technique | Pinch, 45–90 degrees, slow push, no massage |
| Timing | Same time daily; morning suits most |
| Steady state | 4–6 weeks; test the trough after that, not before |
Drawing oil through a 29-gauge needle is slow. Either draw with a larger needle and swap, or accept a minute of patience. Warm the vial in your hand to thin the oil.
What to expect
- Estradiol swings shrink; many people drop an aromatase inhibitor entirely after switching.
- Hematocrit climbs more slowly at the same weekly total.
- Water, mood and libido stop cycling through the week.
- Trough bloodwork reads close to the average, which makes numbers easier to interpret.
- The day-two “high” from a big injection disappears. Some miss it.
Trade-offs
More injections means more sharps, more site rotation and zero tolerance for forgetting. Oil in subcutaneous fat occasionally forms a lump that takes a day or two to disperse; growing redness or heat is a site infection, treated as such. Travel needs planning. None of this is hard, but it has to become a habit like brushing teeth.
Who it suits
Anyone using a medium ester who has estrogen swings, a rising hematocrit, or blood pressure creeping up. Anyone who wants the cleanest possible bloodwork at a given weekly amount. Not for people who cannot inject daily, and pointless for undecanoate.
Frequently asked questions
Does microdosing use less testosterone?
No. It is the same weekly amount divided into smaller, more frequent doses. Some people find they need a little less for the same trough because nothing is wasted on peaks, but the concept is about the curve, not the total.
Which esters work for microdosing?
Enanthate or cypionate: a half-life of several days means each small dose stacks smoothly onto the last. Propionate also works but clears so fast that missing a day shows. Undecanoate is too slow to make daily dosing meaningful.
How do I split a weekly amount?
Divide by the number of injections. A weekly 1 mL becomes about 0.14 mL daily or 0.29 mL every other day. Use a 1 mL insulin syringe with 0.01 mL markings to measure, and expect a few weeks before levels settle at the new flat line.
Where do I inject subcutaneously?
Fat of the lower abdomen (a hand's width from the navel) or the outer thigh, pinched, needle at 45–90 degrees, slow push. Rotate around the abdomen so no spot is used twice in a week. Small lumps that fade in a day or two are normal; growing redness is not.
What are the downsides?
Seven or more injections a week instead of one, so adherence has to be automatic. More sharps. Slightly higher chance of site irritation from oil in fat. Travel is harder. And the flat curve removes the peak some people enjoy for training drive.
Sources
- Comparison of outcomes for hypogonadal men treated with intramuscular testosterone cypionate versus subcutaneous testosterone enanthate. 2021.
- Serum testosterone concentrations remain stable between injections in patients receiving subcutaneous testosterone. Journal of the Endocrine Society, 2017.
- A 52-week study of dose-adjusted subcutaneous testosterone enanthate in oil self-administered via disposable auto-injector. 2018.
- Safety of a new subcutaneous testosterone enanthate auto-injector: results of a 26-week study. Journal of Sexual Medicine, 2019.
- Kicman AT. Pharmacology of anabolic steroids. British Journal of Pharmacology, 2008.